Abbott Launches XIENCE PRIME Drug Eluting Stent

Abbott has announced at the European Society of Cardiology Congress the availability of its XIENCE PRIME Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease. XIENCE PRIME, which received CE Mark in June, offers a novel stent design and a delivery system designed for greater flexibility and enhanced deliverability. XIENCE PRIME is available in Europe and in select countries throughout Asia-Pacific and Latin America.

Antonio Bartorelli, director of the interventional cardiology department of centro cardiologico monzino, University of Milan, said: Abbott’s XIENCE PRIME is an improvement in design, deliverability and conformability, all of which can be distinctly observed during coronary stent procedures, in both everyday and complex lesions. XIENCE PRIME is designed to be easily deliverable even in complex cases and very long lesions.

XIENCE PRIME utilizes the same well-studied drug and proven biocompatible polymer as Abbott’s market-leading XIENCE V® Everolimus Eluting Coronary Stent System. XIENCE PRIME is based upon the well-tested design used in the MULTI-LINK VISION family of stents, which is the most widely used stent platform in the world – more than 2 million of Abbott’s cobalt chromium stents have been implanted worldwide.